Safety and effectiveness of mycophenolate in systemic sclerosis. A systematic review

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Omair, Mohammed A ^a,c   Alahmadi, Abdulaziz ^a   Johnson, Sindhu R ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; PENICILLAMINE; RECOMBINANT RELAXIN;

ABDOMINAL PAIN; ANEMIA; ARTICLE; ASPERGILLOSIS; BACTERIAL PNEUMONIA; BONE MARROW SUPPRESSION; CHRONIC BRONCHITIS; CLINICAL TRIAL (TOPIC); CYTOPENIA; DIARRHEA; DIFFUSING CAPACITY OF CARBON MONOXIDE; DISEASE ASSESSMENT; DISEASE DURATION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; EYE INFECTION; FORCED VITAL CAPACITY; GASTROESOPHAGEAL REFLUX; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG DISEASE; LUNG FIBROSIS; LYMPHOCYTOPENIA; MODIFIED RODNAN SKIN SCORE; NAUSEA; NEUTROPENIA; PSEUDOOBSTRUCTION; RESPIRATORY TRACT PARAMETERS; SKIN DISEASE; SKIN INFECTION; SURVIVAL RATE; SYSTEMATIC REVIEW; SYSTEMIC SCLEROSIS; TOTAL LUNG CAPACITY; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; FEMALE; GASTROINTESTINAL DISEASE; LUNG FUNCTION TEST; MALE; META ANALYSIS; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; SCLERODERMA, SYSTEMIC; SKIN; TREATMENT OUTCOME;

FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; SKIN; TREATMENT OUTCOME;

EID: 84929192281     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124205     Document Type: Article

References (55)

1. Chizzolini C. T cells, B cells, and polarized immune response in the pathogenesis of fibrosis and systemic sclerosis. Curr Opin Rheumatol. 2008; 20: 707-712. doi: 10.1097/BOR.0b013e32830c45ae PMID: 18946333
2. Senecal JL, Henault J, Raymond Y. The pathogenic role of autoantibodies to nuclear autoantigens in systemic sclerosis (scleroderma). J Rheumatol. 2005; 32: 1643-1649. PMID: 16142854
3. Quillinan NP, Denton CP. Disease-modifying treatment in systemic sclerosis: current status. Curr Opin Rheumatol. 2009; 21: 636-641. doi: 10.1097/BOR.0b013e3283310d57 PMID: 19726995
4. Phumethum V, Jamal S, Johnson SR. Biologic therapy for systemic sclerosis: a systematic review. J Rheumatol. 2011; 38: 289-296. doi: 10.3899/jrheum.100361 PMID: 21041277
5. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000; 47: 85-118. PMID: 10878285
6. Hueso M, Bover J, Seron D, Gil-Vernet S, Sabate I, Fulladosa X, et al. Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function. Transplantation. 1998; 66: 1727-1731. PMID: 9884267
7. Djamali A, Vidyasagar A, Yagci G, Huang LJ, Reese S.Mycophenolic acidmay delay allograft fibrosis by inhibiting transforming growth factor-beta1-induced activation of Nox-2 through the nuclear factor-kappaB pathway. Transplantation. 2010; 90: 387-393. doi: 10.1097/TP.0b013e3181e6ae0a PMID: 20548261
8. Rosenbloom J, Jimenez SA. Molecular ablation of transforming growth factor beta signaling pathways by tyrosine kinase inhibition: the coming of a promising new era in the treatment of tissue fibrosis. Arthritis Rheumatol. 2008; 58: 2219-2224. doi: 10.1002/art.23634 PMID: 18668575
9. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007; 46: 13-58. PMID: 17201457
10. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 2012; 64: 797-808. doi: 10.1002/acr.21664 PMID: 22556106
11. Sanford M, Keating GM. Enteric-coated mycophenolate sodium: a review of its use in the prevention of renal transplant rejection. Drugs. 2008; 68: 2505-2533. doi: 10.2165/0003495-200868170-00007 PMID: 19016576
12. Arns W, Breuer S, Choudhury S, Taccard G, Lee J, Binder V, et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant. 2005; 19: 199-206. PMID: 15740555
13. Bunnapradist S, Ambuhl PM. Impact of gastrointestinal-related side effects on mycophenolate mofetil dosing and potential therapeutic strategies. Clin Transplant 2008; 22: 815-821. doi: 10.1111/j.1399-0012.2008.00892.x PMID: 18798850
14. Forbes A, Marie I. Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. Rheumatology. 2009; 48 Suppl 3: iii36-39. doi: 10.1093/rheumatology/ken485 PMID: 19487222
15. Omair MA, Lee P. Effect of gastrointestinalmanifestations on quality of life in 87 consecutive patients with systemic sclerosis. J Rheumatol. 2012; 39: 992-996. doi: 10.3899/jrheum.110826 PMID: 22467930
16. Johnson SR, Glaman DD, Schentag CT, Lee P. Quality of life and functional status in systemic sclerosis compared to other rheumatic diseases. J Rheumatol. 2006; 33: 1117-1122. PMID: 16622903
17. Kowal-Bielecka O, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009; 68: 620-628. doi: 10.1136/ard.2008.096677 PMID: 19147617
18. Tzouvelekis A, Galanopoulos N, Bouros E, Kolios G, Zacharis G, Ntolios P et al. Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a metaanalysis. Pulmo Med 2012; 2012: 143637. doi: 10.1155/2012/143637 PMID: 22655194
19. Stratton RJ, Wilson H, Black CM. Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology. 2001; 40: 84-88. PMID: 11157146
20. Mendoza FA, Nagle SJ, Lee JB, Jimenez SA. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol 2012; 39: 1241-1247. doi: 10.3899/jrheum.111229 PMID: 22467932
21. Derk CT, Grace E, Shenin M, Naik M, Schulz S, Xiong W, et al. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology. 2009; 48: 1595-1599. doi: 10.1093/rheumatology/kep295 PMID: 19846575
22. Simeon-Aznar CP, Fonollosa-Pla V, Tolosa-Vilella C, Selva-O'Callaghan A, Solans-Laque R, Vilardell-Tarres M.Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. Clin Rheumatol. 2011; 30 (11): 1393-1398. doi: 10.1007/s10067-011-1823-1 PMID: 21881859
23. Herrick AL, Lunt M, Whidby N, Ennis H, Silman A, McHugh N, et al. Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis. J Rheumatol. 2010; 37: 116-124. doi: 10.3899/jrheum.090668 PMID: 19955050
24. Liossis SNC, Bounas A, Andonopoulos AP. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology 2006; 45 (8): 1005-1008. PMID: 16490756
25. Vanthuyne M, Blockmans D, Westhovens R, Roufosse F, Cogan E, Coche E, et al. A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis. Clin Exp Rheumatol 2007; 25: 287-292. PMID: 17543155
26. Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. CHEST 2008; 133: 455-460. PMID: 18071023
27. Nihtyanova SI, Brough GM, Black CM, Denton CP. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis - A retrospective analysis. Rheumatology 2007; 46 (3): 442-445. PMID: 16899504
28. Zamora AC, Wolters PJ, Collard HR, Connolly MK, Elicker BM, Webb WR, et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Resp Med 2008, 102: 150-155.
29. Koutroumpas A, Ziogas A, Alexiou I, Barouta G, Sakkas LI. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol. 2010; 29: 1167-1168. doi: 10.1007/s10067-010-1498-z PMID: 20532938
30. Berezne A, Ranque B, Valeyre D, Brauner M, Allanore Y, Launay D, et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: A retrospective multicenter open-label study. J Rheumatol. 2008; 35: 1064-1072. PMID: 18464307
31. Le EN, Wigley FM, Shah AA, Boin F, Hummers LK. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2011; 70 (6): 1104-1107. doi: 10.1136/ard.2010.142000 PMID: 21378404
32. Panopoulos ST, Bournia VK, Trakada G, Giavri I, Kostopoulos C, Sfikakis PP. Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study. Lung 2013; 191: 483-489. doi: 10.1007/s00408-013-9499-8 PMID: 23925736
33. Plastiras SC, Vlachoyiannopoulos PG, Tzelepis GE (2006) Mycophenolate mofetil for interstitial lung disease in scleroderma. Rheumatology 45: 1572. PMID: 16998235
34. Busquets J, Del Galdo F, Kissin EY, Jimenez SA. Assessment of tissue fibrosis in skin biopsies from patients with systemic sclerosis employing confocal laser scanning microscopy: an objective outcome measure for clinical trials? Rheumatology 2010; 49: 1069-1075. doi: 10.1093/rheumatology/keq024 PMID: 20202926
35. Gonzalez-Nieto JA, Martin-Suarez IJ, Gil-Munoz FL. [Efficacy of mycophenolate associated with methotrexate as a maintenance treatment for systemic sclerosis-associated interstitial lung disease]. Arch Bronconeumol 2011; 47: 575. doi: 10.1016/j.arbres.2011.06.007 PMID: 21821334
36. Cuomo G, Abignano G, Iudici M, Petrillo A, Valentini G. Effectiveness and safety of mycophenolate mofetil in the treatment of interstitial lung disease in patients with systemic sclerosis. Arthritis and Rheumatism Conference: American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting, ACR/ARHP 09 Atlanta, GA United States. 2009; 60: 1735.
37. Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci. 2009; 337 (5): 329-335. doi: 10.1097/MAJ.0b013e31818d094b PMID: 19295413
38. Gulamhusein A, Pope JE. Squamous cell carcinomas in 2 patients with diffuse scleroderma treated with mycophenolate mofetil. J Rheumatol. 2009; 36: 460-462. doi: 10.3899/jrheum.080611 PMID: 19208586
39. Bandelier C, Guerne PA, Genevay S, Finckh A, Gabay C. Clinical experience with mycophenolate mofetil in systemic autoimmune conditions refractory to common immunosuppressive therapies. Swiss Med Wkly 2009; 139: 41-46. doi: smw-12441 PMID: 19169902
40. Cuomo G, Abignano G, Valentini G. Early onset neutropenia after mycophenolate mofetil in systemic sclerosis. Rheumatol Int 2009; 29 (12): 1529-1530. doi: 10.1007/s00296-009-0879-6 PMID: 19247660
41. Nikpour M, Hissaria P, Byron J, Sahhar J, Micallef M, PaspaliarisW, et al. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther 2011; 13: R211. doi: 10.1186/ar3544 PMID: 22189167
42. Swigris JJ, Olson AL, Fischer A, Lynch DA, Cosgrove GP, Frankel SK, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. CHEST 2006; 130: 30-36. PMID: 16840379
43. Gonzalez-Nieto JA, Martin-Suarez IJ, Gil-Munoz FL. Efficacy of Mycophenolate Associated with Methotrexate as a Maintenance Treatment for Systemic Sclerosis-Associated Interstitial Lung Disease. [Spanish]. Arch Bronconeumol. 2011; 47 (11): 575. doi: 10.1016/j.arbres.2011.06.007 PMID: 21821334
44. Medsger TA Jr., Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999; 26: 2159-2167. PMID: 10529133
45. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf. 2001; 24: 645-663. PMID: 11522119
46. Bunnapradist S, Ambuhl PM. Impact of gastrointestinal-related side effects on mycophenolate mofetil dosing and potential therapeutic strategies. Clin Transplant 2008; 22: 815-821. doi: 10.1111/j.1399-0012.2008.00892.x PMID: 18798850
47. Khanna D, Hays RD, Maranian P, Seibold JR, Impens A, Mayes MD, et al. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum 2009; 61: 1257-1263. doi: 10.1002/art.24730 PMID: 19714600
48. Houssiau FA, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R. et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010; 69: 2083-2089. doi: 10.1136/ard.2010.131995 PMID: 20833738
49. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365: 1886-1895. doi: 10.1056/NEJMoa1014460 PMID: 22087680
50. Zeher M, Doria A, Lan J, Aroca G, Jayne D, Boletis I. et al. Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus 2011; 20: 1484-1493. doi: 10.1177/0961203311418269 PMID: 21976398
51. Roos N, Poulalhon N, Farge D, Madelaine I, Mauviel A, Verrecchia F. In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil. J Pharmacol Exp Ther. 2007; 321 (2): 583-589. PMID: 17272676
52. Petrova DT, Brandhorst G, Brehmer F, Gross O, Oellerich M, Armstrong VW. Mycophenolic acid displays IMPDH-dependent and IMPDH-independent effects on renal fibroblast proliferation and function. Ther Drug Monit 2010; 32: 405-412. doi: 10.1097/FTD.0b013e3181e44260 PMID: 20592645
53. Badid C, Vincent M, McGregor B, Melin M, Hadj-Aissa A, Veysseyre C, et al. Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int 2000; 58: 51-61. PMID: 10886549
54. Phumethum V, Jamal S, Johnson SR. Biologic therapy for systemic sclerosis: a systematic review. J Rheumatol 2011; 38: 289-296. doi: 10.3899/jrheum.100361 PMID: 21041277
55. Omair MA, Phumethum V, Johnson SR. Long-term safety and effectiveness of tumour necrosis factor inhibitors in systemic sclerosis patients with inflammatory arthritis. Clin Exp Rheumatol 2012; 30: S55-59. PMID: 22691210